Sitryx Therapeutics Receives FDA Clearance to Advance SYX-5219 Into Phase 1b Trial for Atopic Dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...

October 03, 2025 | Friday | News
Draig Therapeutics Secures FDA Clearance to Launch Phase 2 Trial of DT-101 for Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...

October 03, 2025 | Friday | News
Igyxos Biotherapeutics Secures €5.7M France 2030 Grant to Advance Infertility Antibody Therapy

Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has...

October 03, 2025 | Friday | News
Kynexis Doses First Patient in Phase 2 Trial of KYN-5356 for Cognitive Impairment Associated with Schizophrenia

Kynexis, a clinical-stage biotechnology company focused on precision therapeutics for brain diseases, announced that the first patient has been dosed in ...

October 01, 2025 | Wednesday | News
VERAXA Biotech and Secarna Pharmaceuticals Form Strategic Alliance to Develop Next-Generation Antibody Oligonucleotide Conjugates

VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH,...

October 01, 2025 | Wednesday | News
ME Therapeutics Secures U.S. Patent for Lead G-CSF Antibody Candidate to Advance Cancer Immunotherapies

ME Therapeutics Holdings Inc. a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased ...

September 29, 2025 | Monday | News
Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies

Avant Technologies Inc. announced a pivotal evolution in its business direction, emphasizing strategic partnerships through joint ventures and licensing ...

September 26, 2025 | Friday | News
European Commission Approves Lilly’s Kisunla™ (donanemab) for Early Symptomatic Alzheimer’s Disease

Approved for use in the earliest symptomatic stages, Kisunla is the only once-monthly amyloid plaque–targeting therapy with evidence supporting tre...

September 26, 2025 | Friday | News
Actio Biosciences Doses First Participant in Phase 1a Trial of ABS-1230 for KCNT1-Related Epilepsy

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule th...

September 24, 2025 | Wednesday | News
Illumina Expands Global CDx Partnerships to Advance KRAS-Targeted Precision Oncology

Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the T...

September 24, 2025 | Wednesday | News
Revvity and Profluent Join Forces to Advance AI-Enhanced Base Editing with Pin-point™ Platform

Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development o...

September 23, 2025 | Tuesday | News
Esperion and Otsuka Secure MHLW Approval for NEXLETOL® in Japan to Treat Hypercholesterolemia

Esperion announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® ...

September 22, 2025 | Monday | News
Alvotech and Fuji Pharma Secure Japanese Approval for Three New Biosimilars: Denosumab, Golimumab, and Aflibercept

Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced th...

September 22, 2025 | Monday | News
Sunflower Therapeutics and SK bioscience Achieve First Milestone in Development of Cost-Effective 10-Valent HPV Vaccine

 Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applic...

September 19, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close